A carregar...
The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma
Metastatic pancreatic adenocarcinoma remains one of the deadliest cancer diagnoses with 5-year survival rates as low as 3%. For decades, gemcitabine remained the mainstay of systemic therapy before the approvals of FOLFIRINOX and gemcitabine with nab-paclitaxel. Despite these advances in the early 2...
Na minha lista:
| Publicado no: | Ann Pancreat Cancer |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7720884/ https://ncbi.nlm.nih.gov/pubmed/33294843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/apc-2020-pda-05 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|